{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:23:02Z","timestamp":1790310182330,"version":"4.1.0"},"reference-count":76,"publisher":"Frontiers Media SA","issue":"24","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Coordination for the Improvement of Higher Education Personnel, Brazil","award":["Financing Code 001"],"award-info":[{"award-number":["Financing Code 001"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Exp Biol Med (Maywood)"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Hemophilia A (factor VIII [FVIII] deficiency) and hemophilia B (factor IX [FIX] deficiency) are the X-linked recessive bleeding disorders that clinically manifest with recurrent bleeding, predominantly into muscles and joints. In its severe presentation, when factor activity is less than 1% of normal, hemophilia presents with spontaneous musculoskeletal bleeds and may progress to debilitating chronic arthropathy. Management of hemophilia has changed profoundly in the past decades. From on-demand to prophylactic factor concentrate replacement, the treatment goal shifted from controlling bleeds to preventing bleeds and improving quality of life. In this new scenario, gene therapy has arisen as a paradigm-changing therapeutic option, a one-time treatment with the potential to achieve sustained coagulation FVIII or FIX expression even within the normal range. This review discusses the critical impact of adeno-associated virus (AAV) gene transfer in hemophilia care, including the recent clinical outcomes, changes in disease perceptions, and its treatment burden. We also discuss the challenging scenario of the AAV-directed immune response in the clinical setting and potential strategies to improve the long-lasting efficacy of hemophilia gene therapy efficacy.<\/jats:p>","DOI":"10.1177\/15353702221147565","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:35:28Z","timestamp":1674520528000},"page":"2223-2232","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Gene therapy for hemophilia: looking beyond factor expression"],"prefix":"10.3389","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0350-8171","authenticated-orcid":false,"given":"Gabriela G","family":"Yamaguti-Hayakawa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, School of Medical Sciences, University of Campinas, UNICAMP, Campinas 13083-878, Brazil"},{"name":"Hemocentro UNICAMP, University of Campinas, Campinas 13083-878, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-0675","authenticated-orcid":false,"given":"Margareth C","family":"Ozelo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medical Sciences, University of Campinas, UNICAMP, Campinas 13083-878, Brazil"},{"name":"Hemocentro UNICAMP, University of Campinas, Campinas 13083-878, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"bibr1-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00278-x"},{"key":"bibr2-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"bibr3-15353702221147565","unstructured":"PR Newswire. First gene therapy for adults with severe hemophilia A, BioMarin\u2019s ROCTAVIAN\u2122 (valoctocogene roxaparvovec), approved by European Commission (EC), https:\/\/investors.biomarin.com\/2022-08-24-First-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A,BioMarins-ROCTAVIAN-TM-valoctocogene-roxaparvovec-Approved-by-European-Commission-EC"},{"key":"bibr4-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046"},{"key":"bibr5-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708483"},{"key":"bibr6-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104205"},{"key":"bibr7-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14391"},{"key":"bibr8-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113708"},{"key":"bibr9-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708538"},{"key":"bibr10-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804419"},{"key":"bibr11-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004625"},{"key":"bibr12-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119913"},{"key":"bibr13-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13504"},{"key":"bibr14-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100759"},{"key":"bibr15-15353702221147565","volume":"4","author":"Barrowcliffe TW","year":"1998","journal-title":"Haemophilia"},{"key":"bibr16-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.3406_1.x"},{"key":"bibr17-15353702221147565","volume":"4","author":"Mikaelsson M","year":"1998","journal-title":"Haemophilia"},{"key":"bibr18-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137648"},{"key":"bibr19-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005683"},{"key":"bibr20-15353702221147565","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Chambost H, Chou S, Dunn A, von Drygalski A, Kaczmarek R, Kenet G, Laffan M, Leavitt A, Madan B, Mason J, Oldenburg J, Ozelo M, Peyvandi F, Quon D, Reding M, Shapiro S, Yu H, Robinson T, Pipe S. Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: results from GENEr8-1. In: ISTH 2022 congress, 2022, https:\/\/abstracts.isth.org\/abstract\/relationship-between-transgene-produced-fviii-and-bleeding-rates-2-years-after-gene-transfer-with-valoctocogene-roxaparvovec-results-from-gener8-1\/","DOI":"10.1016\/j.rpth.2023.100459"},{"key":"bibr21-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904377"},{"key":"bibr22-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13605"},{"key":"bibr23-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007435"},{"key":"bibr24-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.169"},{"key":"bibr25-15353702221147565","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Ozelo MC, Peyvandi F, Jayaram K, Yu H, Robinson TM, Wong WY, Pipe SW, and on behalf of the GENEr8-1 trial group. Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 two-year analysis. In: EAHAD 2022 congress: haemophilia, 2022, https:\/\/genetherapy.isth.org\/efficacy-and-safety-of-valoctocogene-roxaparvovec-gene-transfer-for-severe-haemophilia-a-results-from-the-gener8-1-two-year-analysis","DOI":"10.1055\/s-0042-1760620"},{"key":"bibr26-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12531"},{"key":"bibr27-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"bibr28-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2017.11.003"},{"key":"bibr29-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02539.x"},{"key":"bibr30-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001384"},{"key":"bibr31-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12526"},{"key":"bibr32-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02808.x"},{"key":"bibr33-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13811"},{"key":"bibr34-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14642"},{"key":"bibr35-15353702221147565","unstructured":"Basic documents: forty-ninth edition\n                      (including amendments adopted up to 31 May 2019). Geneva: World Health Organization, 2020"},{"key":"bibr36-15353702221147565","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S357555"},{"key":"bibr37-15353702221147565","doi-asserted-by":"crossref","unstructured":"Itzler R, Miller J, Robson R, Monahan P, Pipe S. Improvements in health-related quality of life in adults with severe or moderately severe hemophilia B after receiving etranacogene dezaparvovec gene therapy. In: ISTH 2022 congress, 2022, https:\/\/abstracts.isth.org\/abstract\/improvements-in-health-related-quality-of-life-in-adults-with-severe-or-moderately-severe-hemophilia-b-after-receiving-etranacogene-dezaparvovec-gene-therapy\/","DOI":"10.1055\/s-0042-1760525"},{"key":"bibr38-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13027"},{"key":"bibr39-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13960"},{"key":"bibr40-15353702221147565","doi-asserted-by":"crossref","DOI":"10.1111\/hae.13758","volume":"25","author":"Croteau SE","year":"2019","journal-title":"Haemophilia"},{"key":"bibr41-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02692.x"},{"key":"bibr42-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02713.x"},{"key":"bibr43-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13220"},{"key":"bibr44-15353702221147565","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1016228"},{"key":"bibr45-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010864"},{"key":"bibr46-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1721508"},{"key":"bibr47-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018021345"},{"key":"bibr48-15353702221147565","unstructured":"Laffan MRS, Lester W, Symington E, Madan B, Hart D, Li M, Robinson T, Pierce G, Wong W. Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A. In: ISTH 2022 congress, 2022, https:\/\/abstracts.isth.org\/abstract\/hemostatic-results-for-up-to-6-years-following-treatment-with-valoctocogene-roxaparvovec-an-aav5-hfviii-sq-gene-therapy-for-severe-hemophilia-a\/"},{"key":"bibr49-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.010"},{"key":"bibr50-15353702221147565","doi-asserted-by":"publisher","DOI":"10.2174\/156652307782151425"},{"key":"bibr51-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120474"},{"key":"bibr52-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.026"},{"key":"bibr53-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.287"},{"key":"bibr54-15353702221147565","volume":"12","author":"Manno CS","year":"2006","journal-title":"Nat Med"},{"key":"bibr55-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.008"},{"key":"bibr56-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.05.009"},{"key":"bibr57-15353702221147565","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658399"},{"key":"bibr58-15353702221147565","unstructured":"Miesbach W, Leebeek FWG, Recht M, Key NS, Lattimore S, Castaman G, Coppens M, Cooper D, Slawka S, Verweij S, Gut R, Dolmetsch R, Li Y, Monahan PE, Pipe SW, Investigators H-B. Final analysis from the pivotal phase 3 HOPE-B gene therapy trial: stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B. In: 15th annual congress of EAHAD: haemophilia, 2022, pp. 99\u2013100, https:\/\/genetherapy.isth.org\/final-analysis-from-the-pivotal-phase-3-hope-b-gene-therapy-trial-stable-steady-state-efficacy-and-safety-of-etranacogene-dezaparvovecin-adults-with-severe-or-moderately-severe-hemophilia-b"},{"key":"bibr59-15353702221147565","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112471"},{"key":"bibr60-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.031"},{"key":"bibr61-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.01.004"},{"key":"bibr62-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.244"},{"key":"bibr63-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0911-7"},{"key":"bibr64-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2014.09.003"},{"key":"bibr65-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4214.bloodjournal84124214"},{"key":"bibr66-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150541"},{"key":"bibr67-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2004.00710.x"},{"key":"bibr68-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13193"},{"key":"bibr69-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14470"},{"key":"bibr70-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288001"},{"key":"bibr71-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.240"},{"key":"bibr72-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588194"},{"key":"bibr73-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05107-11"},{"key":"bibr74-15353702221147565","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14056"},{"key":"bibr75-15353702221147565","unstructured":"bluebird bio I. bluebird bio receives FDA accelerated approval for SKYSONA\n                      \u00ae\n                      gene therapy for early, active cerebral adrenoleukodystrophy (CALD). 2022, https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-receives-fda-accelerated-approval-skysonar-gene"},{"key":"bibr76-15353702221147565","unstructured":"Administration USFaD. FDA approves first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions, 2022, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cell-based-gene-therapy-treat-adult-and-pediatric-patients-beta-thalassemia-who#:~:text=Today%2C%20the%20U.S.%20Food%20and,regular%20red%20blood%20cell%20transfusions."}],"container-title":["Experimental Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15353702221147565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15353702221147565","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15353702221147565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:59:23Z","timestamp":1777568363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ebm-journal.org\/journals\/experimental-biology-and-medicine\/articles\/10.1177\/15353702221147565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":76,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/15353702221147565"],"URL":"https:\/\/doi.org\/10.1177\/15353702221147565","relation":{},"ISSN":["1535-3702","1535-3699"],"issn-type":[{"value":"1535-3702","type":"print"},{"value":"1535-3699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}